Lifesci Capital Initiates Coverage on Hemab Therapeutics (NASDAQ:COAG)

Stock analysts at Lifesci Capital started coverage on shares of Hemab Therapeutics (NASDAQ:COAG) in a report issued on Monday, Benzinga reports. The brokerage set an “outperform” rating and a $65.00 price target on the stock. Lifesci Capital‘s price objective would indicate a potential upside of 32.60% from the company’s previous close.

COAG has been the topic of a number of other research reports. Weiss Ratings lowered shares of Hemab Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, September 25th. Wedbush lifted their price target on Hemab Therapeutics from $55.00 to $64.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 12th. HC Wainwright boosted their price objective on Hemab Therapeutics from $52.00 to $60.00 and gave the company a “buy” rating in a report on Tuesday, August 11th. Rodman & Renshaw started coverage on Hemab Therapeutics in a report on Monday, October 12th. They issued a “buy” rating and a $56.00 price objective for the company. Finally, JPMorgan Chase & Co. assumed coverage on Hemab Therapeutics in a research note on Thursday, October 15th. They set an “overweight” rating and a $70.00 price objective on the stock. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Hemab Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $56.00.

Hemab Therapeutics Stock Performance

Shares of NASDAQ:COAG opened at $49.02 on Monday. The company has a market capitalization of $2.29 billion and a price-to-earnings ratio of -1.98. The stock has a fifty day moving average of $37.50. Hemab Therapeutics has a 12-month low of $23.00 and a 12-month high of $55.42.

Hemab Therapeutics (NASDAQ:COAG) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.17). As a group, analysts forecast that Hemab Therapeutics will post -3.10 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Hemab Therapeutics

A number of institutional investors have recently modified their holdings of COAG. Russell Investments Group Ltd. bought a new stake in shares of Hemab Therapeutics during the 3rd quarter valued at about $46,000. China Universal Asset Management Co. Ltd. lifted its holdings in Hemab Therapeutics by 77.8% in the third quarter. China Universal Asset Management Co. Ltd. now owns 6,400 shares of the company’s stock worth $209,000 after acquiring an additional 2,800 shares during the last quarter. Squarepoint Ops LLC bought a new position in Hemab Therapeutics in the second quarter worth about $230,000. Profund Advisors LLC acquired a new position in Hemab Therapeutics in the third quarter valued at approximately $246,000. Finally, The Manufacturers Life Insurance Company acquired a new position in Hemab Therapeutics in the second quarter valued at approximately $688,000.

About Hemab Therapeutics

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing treatments for serious bleeding disorders. The company’s research is aimed at addressing conditions in which patients experience inadequate clot formation or difficulty controlling bleeding, including rare inherited and acquired disorders.

Hemab’s lead investigational program, HMB-001, is being developed as a potential treatment for Glanzmann thrombasthenia, a rare inherited platelet disorder that can cause severe and recurring bleeding.